Hetrombopag

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Hetrombopag 是一种有效的、选择性的、口服活性的血小板生成素 (TPO) 受体激动剂。

Hetrombopag is a potent, selective, orally-active Thrombopoietin (TPO) receptor agonist; specifically stimulates proliferation and/or differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells, with low nanomolar EC50 values through stimulation of STAT, PI3K and ERK signalling pathways; specifically enhances the viability and promoted the growth of 32D-MPL cells in hollow fibres implanted in nude mice, exhibiting much higher potency than eltrombopag in vivo.Other Indication Phase 2 Clinical.

——

——

——

Immunology/Inflammation

CD110

CD110

Other Indications

Other Disease

2114365-78-3

458.474

C25H22N4O5

>98% (HPLC)

In Vitro:?DMF : 6.25 mg/mL (13.63 mM)

CC1=C(C(=O)N(N1)C2=CC3=C(CCCC3)C=C2)N=NC4=CC=CC(=C4O)C5=CC=C(O5)C(=O)O

5-[(5E)-5-[[5-methyl-3-oxo-2-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]furan-2-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years